Eurofins Expands Its Leading Footprint in Biopharmaceutical Products Testing with the Acquisition of ams Laboratories in Aust...
11 March 2016 - 5:30PM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF):
Eurofins Scientific (EUFI.PA), the world leader in
biopharmaceutical products testing, announces its entry into the
biopharmaceutical products testing market in the Asia Pacific
region with the acquisition of ams Laboratories Pty Ltd. (“ams
Laboratories”), the leading independent analytical and cGMP Quality
Control (QC) services provider for biopharmaceutical products and
medical devices in Australia.
Founded 20 years ago, ams Laboratories has grown rapidly to
become one of the top three, and the largest pure-play
biopharmaceutical products testing provider in the domestic market,
serving the biopharma and medical devices industries. The company
employs 45 staff across its 2 sites in Sydney and Brisbane. In the
past decade, it has grown well above Eurofins’ annual organic
growth objective, and generated revenues in excess of EUR 5m for
the fiscal year 2015, the majority of which is from
biopharmaceutical products testing. The company is also active in
medical device testing, as well as in probiotics and nutraceutical
testing.
The acquisition of ams Laboratories provides Eurofins with a
strong entry platform to deploy its market-leading
biopharmaceutical testing capabilities to support the
pharmaceutical and biotechnology industries in the Asia Pacific
region. Furthermore, it allows Eurofins to expand into medical
device testing in the region, which is entirely complementary to
its existing biopharma capabilities. The company therefore presents
an excellent geographical and operational fit for the Group. ams
Laboratories further expands the Eurofins global biopharma service
offering, and will enable the Group to further leverage its
existing client relationships in Europe and North America, and
accelerate its expanding client reach in Asia Pacific, which still
represents a vast potential growth market for drug development.
In return, ams will benefit from access to the complete range of
Eurofins’ portfolio of services as the global reference in
biopharmaceutical testing, which will enable it to expand its
service offering and its footprint in the biopharmaceutical and
medical device testing markets, as well as in the nutraceutical
testing market in the region.
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition
of ams Laboratories provides Eurofins a platform to deploy its
renowned capabilities in biopharmaceutical products testing in the
Asia Pacific region, and reinforces the Group’s global leadership
in the biopharmaceutical products testing market. We look forward
to expanding and strengthening ams Laboratories’ footprint by
providing them access to the full range of Eurofins’
capabilities.”
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and
pharmaceutical products testing. It is also one of the global
market leaders in agroscience, genomics, discovery pharmacology and
central laboratory services. In addition, Eurofins is one of the
key emerging players in specialty clinical diagnostic testing in
Europe and the USA.
With over 22,000 staff in more than 225 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products, as well as for innovative clinical
diagnostic. The Group provides its customers with high-quality
services, accurate results on time and expert advice by its highly
qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160310006265/en/
For more information, please visit
www.eurofins.com or contact:Eurofins Investor
Relations+32-2-766 1620ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024